Abstract: The present invention is directed to compositions and methods of treating or preventing diseases or disorders with inhibitors of SHP2, alone, and in combination with other therapeutic agents such as RAS pathway inhibitors (e.g., MEK inhibitors); methods of establishing appropriate treatment plans for subjects based upon the expression of one or more biomarker indicative of SHP2 inhibitor sensitivity; and methods of determining sensitivity to a SHP2 inhibitor based on a phosphorylation status of SHP2.
Type:
Application
Filed:
February 8, 2023
Publication date:
February 22, 2024
Applicant:
Revolution Medicines, Inc.
Inventors:
Robert J. Nichols, Mark A. Goldsmith, Christopher Schulze, Jaqueline Smith, David E. Wildes, Stephen Kelsey, Mallika Singh
Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
Abstract: The present application provides methods of treating urticaria in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which inhibits JAK1, or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
August 4, 2023
Publication date:
February 22, 2024
Inventors:
Cornelius P. Sailer, Kurt Andrew Brown, Vijay Krishna Iyengar, James Lee, Leandro Luiz Dos Santos, Susan Harless Smith
Abstract: Disclosed herein are methods of treating or preventing neurodegenerative disease, neuronal damage, neuroinflammation, or cancer using suppressors of electron leak.
Abstract: A method of treating a JAK-inhibition-responsive condition (such as a hair loss disorder) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of Compound (I) or a pharmaceutically acceptable salt thereof, wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium; and wherein: the subject is receiving a concomitant administration of a CYP3A4 inhibitor; and the therapeutically effective amount of Compound (I), or a pharmaceutically acceptable salt thereof, is not reduced compared to the therapeutically effective amount of Compound (I), or pharmaceutically acceptable salt thereof, that would be administered to the subject in the absence of concomitant administration of a CYP3A4 inhibitor.
Type:
Application
Filed:
October 20, 2023
Publication date:
February 22, 2024
Inventors:
James V. Cassella, Christopher L. Brummel
Abstract: The present invention provides methods and compositions for treating endocrine conditions that result in decreased folate levels in the cerebrospinal fluid. These conditions may be prevented and treated with reduced folates and vitamin B12. Administration of reduced folates and vitamin B12 will prevent or treat cerebrospinal folate deficiency, which is linked to thyroid-related medical conditions. Administration of reduced folates and vitamin B12 will also prevent or treat conditions associated with masked megaloblastic anemia and hypothyroidism, and other conditions brought upon through improper thyroid function. Methods of diagnosing decreased folate levels in individuals are also disclosed.
Abstract: Described herein are certain dosing schedules and amounts that effectively prevent and manage side effects associated with histone deacetylase inhibitor (HDACi) treatment. Optionally, these schedules and dosing regimens include treatment with an antiviral agent.
Type:
Application
Filed:
October 6, 2020
Publication date:
February 22, 2024
Inventors:
Robert MCRAE, Gail L. BROWN, David SLACK, Marshelle Smith WARREN, Richard TRAUGER
Abstract: The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and their use for the treatment of cancer.
Type:
Application
Filed:
March 23, 2023
Publication date:
February 22, 2024
Inventors:
Heike KEILHACK, Sarah K. KNUTSON, Danielle Johnston BLACKWELL, Larisa REYDERMAN, Lone OTTESEN
Abstract: Provided herein are methods of treating and preventing steroid-induced atrophy (e.g., skin atrophy, osteoporosis, etc.) by the administration of PI3K/Akt/mTOR inhibitors and pharmaceutical compositions and combinations therefor.
Abstract: Provided are methods for the parenteral use of 3-methoxy-N-[3-(2-methylpyrazol-3-yl)-4-(2-morpholin-4-ylethoxy)phenyl]benzamide, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, and the sequential use of parenteral and oral formulations of 3-methoxy-N-[3-(2-methylpyrazol-3-yl)-4-(2-morpholin-4-ylethoxy)phenyl]benzamide, or a pharmaceutically acceptable salt, hydrate, or solvate thereof.
Type:
Application
Filed:
December 30, 2021
Publication date:
February 22, 2024
Applicant:
Arena Pharmaceuticals, Inc.
Inventors:
John William Adams, Prodromos Anthopoulos, Kathe Lynn Stauber, Brandon James Walsh
Abstract: A compound or a pharmaceutically acceptable salt thereof for use in a method of treatment of a disease or condition in which signalling through the PI3K? pathway is pathologically implicated in patients, for example cancer and inflammatory or autoimmune diseases. The compound is provided at a specified dose and has been found to have a favourable safety profile in humans, in particular with regard to hepatotoxicity, diarrhoea/colitis, respiratory infections, and hematologic toxicities.
Type:
Application
Filed:
March 29, 2022
Publication date:
February 22, 2024
Inventors:
Catherine PICKERING, Lars VAN DER VEEN, Michael LAHN, Rebeca ZORRILLA, Zoë JOHNSON
Abstract: The present disclosure provides methods of treating cancer with a combination therapies of a SHP2 inhibitor, such as the compound of Formula I, and an FGFR inhibitor, a B-Raf inhibitor, a MEK inhibitor, or a MET inhibitor
Type:
Application
Filed:
December 10, 2021
Publication date:
February 22, 2024
Inventors:
Leenus MARTIN, Leslie Harris BRAIL, Robert Field SHOEMAKER
Abstract: Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and/or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.
Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Abstract: Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof comprising alcaftadine or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
February 28, 2023
Publication date:
February 22, 2024
Inventors:
Avner Ingerman, Frans Janssens, Anton Megens, Mark B. Abelson
Abstract: The present invention provides a pharmaceutical composition for transdermal administration comprising epinastine or a salt thereof as an active ingredient which can maintain the effective concentration of epinastine or a salt thereof in an ocular tissue and stabilize epinastine or a salt thereof in the pharmaceutical composition for a long time.
Abstract: Provided is a method for treating musculoskeletal atrophy in patients suffering from a neurological or neuromuscular disease or disorder by combining testosterone replacement therapy with neuromuscular electrical stimulation of multiple muscle groups and, optionally, physical activity.
Type:
Application
Filed:
November 1, 2023
Publication date:
February 22, 2024
Inventors:
Gail Florence Forrest, William A. Bauman
Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.
Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.
Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.
Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.
Abstract: The present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a drug which is prone to oxidation, said method comprising the addition of an additive to prevent oxidation of the drug which is prone to oxidation. In particular, the present disclosure relates to a method for stabilizing the pH of an aqueous composition comprising a corticosteroid, said method comprising the addition of an additive to prevent oxidation of the corticosteroid. The present disclosure also relates to a composition comprising a corticosteroid and an additive to prevent oxidation of the corticosteroid.
Abstract: A method of treating or preventing one or more symptoms of psychological distress in a subject comprising the step of: a) administering a dose of between 50 mg/day and 200 mg/day cannabidiol for at least one week; wherein the subject has symptoms of at least one of anxiety, stress and/or depression when assessed by a validated scale or biomarker for identifying symptoms of anxiety, stress and/or depression.
Abstract: The present invention is directed to a composition comprising a cannabinoid and hyaluronic acid and a method for use thereof, such as for the treatment and prevention of inflammatory diseases in a subject.
Abstract: [Object] It is an object to provide a highly safe and easy-to-administer pharmaceutical preparation for treating epilepsy, pharmaceutical preparation for treating an autism spectrum disorder, and/or pharmaceutical preparation for treating an anxiety disorder. [Solving Means] A topical preparation containing as an active ingredient at least one selected from the group consisting of sirolimus and a sirolimus derivative is a pharmaceutical preparation that is easy to administer, and is highly safe as a therapeutic agent for epilepsy, an autism spectrum disorder, and/or an anxiety disorder. Suitable examples of the active ingredient include sirolimus, everolimus, temsirolimus, ridaforolimus, and zotarolimus.
Abstract: Embodiments of compositions and methods for the treatment of blood disorders and malignancies in a subject are described herein. In one embodiment, a composition for the treatment of a blood disorder or a malignancy in a subject comprises decitabine, tetrahydrouridine, and an excipient. In another embodiment, a method for the treatment of a blood disorder or a malignancy in a subject comprises the oral administration of a composition comprising decitabine and tetrahydrouridine. In some examples, the composition may be administered 1-3 times weekly.
Type:
Application
Filed:
August 29, 2023
Publication date:
February 22, 2024
Applicant:
The Board of Trustees of the University of Illinois
Abstract: The invention provides respirable dry powder particle formulations comprising polynucleotides preferably prepared by spray drying for delivery to the pulmonary system via inhalation. Preferably, the polynucleotide is RNA.
Type:
Application
Filed:
March 14, 2023
Publication date:
February 22, 2024
Inventors:
Adam Hartman, Fahad Gilani, Kyle LaVigne, Michael M. Lipp
Abstract: Provided a method of treating ocular surface damage caused by an eye disease or eye injury like dry eye disease, chemical or physical injury, infection, neurosensory abnormalities and unspecified etiologies in a subject, comprising administering to said subject a pharmaceutical composition comprising a therapeutically effective amount of microRNA-328 antagonist.
Abstract: Provided herein are gapmer oligomeric compounds for reduction of target RNA in vivo comprising different nucleotide modifications within one or both wing regions. Also provided are methods of using such oligomeric compounds, including use in animals. In certain embodiments, such compound have desirable potency and toxicity characteristics.
Abstract: Molecules for inducing spontaneous calcification of tumor cells and applications thereof. The molecules for inducing spontaneous calcification of tumor cells includes at least two basic units, one of the at least two basic units is a targeting functional unit that targets a molecular fragment of a functional region in the tumor cells/tissues/microenvironments, and the other basic unit is a functional unit for inducing calcification; or molecules for inducing spontaneous calcification of tumor cells comprise at least one basic unit that is both a targeting functional unit and a calcification-inducing functional unit. After calcification of tumor cells occurs, calcium salt deposition on the cell surface will affect metabolism and other physiological processes in tumor cells, leading to apoptosis induction and the suppression of tumor growth. Additionally, after calcification, tumor cells and tissues exhibit improved contrast in clinical images, thereby facilitating early and precise diagnosis of tumor lesions.
Type:
Application
Filed:
December 21, 2021
Publication date:
February 22, 2024
Inventors:
Ben WANG, Jicheng WU, Hanhui LI, Ning TANG
Abstract: A method for relieving joint pain or other discomforts associated with osteoarthritis in a warm-blooded vertebrate includes delivering to the vertebrate by oral ingestion a nutritional supplement consisting essentially of an effective amount of hyaluronic acid (HA), or a salt of digest thereof, a food acceptable carrier and an additive to maintain a pH of the nutritional supplement above 7.0, wherein an effective amount of HA or salt or digest thereof is from about 0.1 ?g per kg to about 400 ?g per kg of body weight.
Abstract: The invention relates to a fibre mixture comprising beta-galactooligosaccharides, inulin, resistant starch and soluble soy polysaccharides and to nutritional compositions comprising such a fibre mixture. The intended use of the fibre mixture and nutritional compositions is for preventing or treating constipation, especially in young children.
Abstract: Described herein are methods for preventing a relapse of cancer in a subject. The methods involve administering to the subject in need thereof a sulfated glycosaminoglycan or the pharmaceutically acceptable salt or ester thereof. In one aspect, the methods described herein prevent the growth or self-renewal of cancer stem cells in a subject. In another aspect, the methods described herein kill active or dormant cancer stem cells in a subject. The methods described herein can be used in combination with chemotherapy and/or radiation. The methods described herein are versatile with respect to preventing the relapse of a number of different cancers.
Abstract: The present disclosure generally relates to a method for reducing the toxicity of polymyxins as a therapeutic agent comprising the step of coadministration of an aminoglycoside; a method for improving the aerosolization of an aminoglycoside comprising the step of combination formulation with a polymyxin; and a process for manufacturing a dry powder composition comprising a polymyxin and aminoglycoside. Pharmaceutical compositions and methods of treatment for lung infections are within the scope of this invention.
Type:
Application
Filed:
October 27, 2021
Publication date:
February 22, 2024
Applicant:
Purdue Research Foundation
Inventors:
Qi ZHOU, Maizbha Uddin AHMED, Mohammad Abul Kalam AZAD, Jian LI
Abstract: The present disclosure relates to methods and complexes for ingestion of an elemental magnesium complex as inverted micellar nanodroplets designed to enhance uptake and cell delivery of active constituents. The complex and methods associated with delivery of the elemental magnesium complex disclosed improves many magnesium deficiencies that include cardiovascular, metabolic, neurohormonal, immune defense and repair systems, digestive, behavioral, and community risks.
Abstract: A method of plasmonic enhanced magnetic nanoparticles hyperthermia (PE-MNH) of M@X core/shell nanoparticles using laser energy. Up on laser exposure of the nanoparticles in solution, the plasmonic shell will heat up and isolate each particle in their own hydrodynamic shell that lead to reducing the inter-particle interaction of the magnetic nanoparticles. This will lead to disaggregated nanoparticle with high dispersity, free movement and rotation in solution as well as giant increase in SAR when the alternating magnetic field within clinical safety limits is applied. Application of this approach has the potential to revolutionize the current treatment regimens by replacing them with plasmonic enhanced magnetic nanoparticles hyperthermia therapy that is more effective, less toxic, and impact survival.
Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 ?g to about 4,000 ?g of zinc, about 40 ?g to about 400 ?g of copper, from about 4 ?g to about 90 ?g of selenium, or from about 1 ?g to about 80 ?g of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.
Type:
Application
Filed:
October 6, 2023
Publication date:
February 22, 2024
Applicant:
American Regent, Inc.
Inventors:
Gopal Anyarambhatla, Richard Lawrence, Jasmina Marinkovic
Abstract: Therapeutic and diagnostic methods are provided, which methods relate to the induction of expression of calreticulin on phagocytic cells. Specifically, the methods relate to macrophage-mediated programmed cell removal (PrCR), the methods comprising increasing PrCR by contacting a phagocytic cell with a toll-like receptor (TLR) agonist; or down-regulating PrCR by contacting a phagocytic cell with an inhibitor of Bruton's tyrosine kinase (BTK). In some embodiments, an activator of TLR signaling or a BTK agonist is provided in combination with CD4 7 blockade.
Type:
Application
Filed:
August 29, 2023
Publication date:
February 22, 2024
Inventors:
Irving L. Weissman, Mingye Feng, Jens-Peter Volkmer
Abstract: The present invention is inter alma concerned with a T cell receptor fusion construct comprising two specific peptidic moieties, one of these two moieties binding to the spike protein from coro-naviruses and binding to ACE2, in particular the spike proteins from SARS-CoV-2 and/or SARS-CoV-1, and one of these moieties being a protein of the T cell receptor complex. A vector comprising the genetic information encoding the T cell receptor fusion construct is also part of the present invention, as well as a process of transfecting or transducing T cells and a modified T cell comprising the T cell receptor fusion construct. Importantly, the present invention also relates to a T cell receptor fusion construct, a vector or a modified T cell for use in the treatment of a disease and in particular for use in the treatment of a disease caused by a coronavirus such as e.g. COVID-19 or SARS.
Type:
Application
Filed:
October 22, 2020
Publication date:
February 22, 2024
Inventors:
Wolfgang SCHAMEL, Ira GODBOLE, Sascha YOUSEFI, Kevin CIMINSKI, Martin SCHWEMMLE
Abstract: The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.
Abstract: Intracellular delivery of a genetic construct to immune cells including: obtaining a deterministic mechanoporation (DMP) platform that includes a substrate having a surface and a plurality of capture sites, each said capture site having a boundary shape at the surface adapted and configured to support thereon a cell, and each said capture site having a bottom and including a sub-micron-scale projection extending from the bottom toward the surface of the substrate, wherein said projection is adapted and configured to penetrate a cell membrane and/or wall of the cell, and wherein the substrate has a plurality of aspiration vias situated at the bottom of the capture sites; introducing the cells to the surface in a liquid media; capturing the cells within the capture sites by applying a first hydrodynamic force; applying a second hydrodynamic force on the captured cell and locally rupturing the membrane and/or wall of the cell with the projection, introducing the genetic construct into the cells, and releasing th
Type:
Application
Filed:
October 30, 2023
Publication date:
February 22, 2024
Inventors:
Masaru P. Rao, Harish G. Dixit, Hideaki Tsutsui, Morgan L. Dundon, Pranee I. Pairs, Stephen J. Forman, Christine E. Brown, Renate Starr, Christopher B. Ballas
Abstract: The present invention describes a method for treating cancer comprising adoptive transfer of tumor antigen specific CD8+ T cells and an oncolytic virus vaccine targeting the same antigen.
Type:
Application
Filed:
November 1, 2023
Publication date:
February 22, 2024
Inventors:
Yonghong WAN, Scott WALSH, Lan CHEN, Omar SALEM, Boris SIMOVIC
Abstract: The present disclosure provides compositions and methods related to chimeric antigen receptors (CARs). In particular, the present disclosure provides CAR-based immunotherapeutic compositions that target tumor cells expressing glypican-3 (GPC3) for the treatment and prevention of cancer.
Abstract: The present disclosure relates to compositions and methods for treating viral infections, or inhibiting, slowing or halting replication of a virus, e.g., an airborne respiratory virus, by administering to a nasal cavity of a subject in need thereof a composition comprising colostrum. The compositions can further comprise an algan polysaccharide, for example fucoidan. The compositions can be in the form of a nasal spray, nasal drops, nasal mist, or a nasal swab.
Abstract: A method of improving joint health in a subject in need thereof comprises administering an exosome-enriched product comprising intact bovine milk-derived exosomes to the subject in need thereof.
Type:
Application
Filed:
December 20, 2021
Publication date:
February 22, 2024
Inventors:
José María LÓPEZ PEDROSA, Ricardo RUEDA CABRERA, Jorge GARCÍA MARTÍNEZ
Abstract: A culture medium composition for expanding hematopoietic stem cells (HSCs) and maintaining self-renewal capacity and differentiation potential of HSCs, a cell population and an application thereof. The culture medium composition comprises a hematopoietic stem cell medium and a small molecule inhibitor of a PDGFR target. The inhibitor of PDGFR can significantly expand HSCs during in-vitro culture, maintaining a high proportion of HSCs with self-renewal capacity, achieving in-vitro expansion of HSCs while maintaining a relatively high proportion of cells with sternness.
Abstract: Described herein are methods for generating human forebrain endothelial cells, compositions comprising the cells, and methods of use thereof in therapy. Provided herein are methods for generation of human embryonic forebrain-like endothelial cells (e.g., periventricular endothelial cells) from human embryonic stem cells; the methods include addition or GABA and WNT7A for efficient differentiation, and isolation of GABRB37CD31+ cell population by FACS.
Abstract: Disclosed is a pharmaceutical composition for preventing or treating angiogenesis-dependent diseases, comprising, as an active ingredient, cardiac stem cells having enhanced angiogenic potential or a culture broth thereof.
Type:
Application
Filed:
March 17, 2021
Publication date:
February 22, 2024
Inventors:
Seung Jin LEE, Heejung KIM, Ji Young SHIN, Jeong Hwa JEON, Chae Won SEO
Abstract: The invention relates to the discovery of a previously unknown population of adipocytes marked by active intracellular Wnt/?-catenin signaling. The present invention provides methods of making populations of adipocytes in which the proportion of these “Wnt+ adipocytes” is much higher than those in naturally occurring populations. Wnt+ adipocytes can be used to improve blood glucose control and exosomes secreted by Wnt+ adipocytes can be administered to reduce blood glucose levels in subjects in need thereof.
Type:
Application
Filed:
December 16, 2021
Publication date:
February 22, 2024
Applicant:
The Administrators of the Tulane Educational Fund